



Date: May 16, 2019

Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

BSE Limited

Department of Corporate Services
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001
Script Code: 524816

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex
Bandra (East)
Mumbai - 400 051
Symbol: NATCOPHARM

Dear Sir/ Madam,

Sub: Intimation of closure of buy-back by Natco Pharma Limited ("**Company**") of its equity shares from open market through the stock exchanges ("**Buy-back**") in accordance with the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018 ("**Buy-back Regulations**")

1. This is in furtherance to (i) our letter dated November 5, 2018 disclosing the outcome of the meeting of the board of directors of the Company ("**Board**") held on the same day (November 5, 2018), that approved *inter alia* the Buy-back; and (ii) our letter dated November 9, 2018 regarding submission of the public announcement dated November 6, 2018 in relation to the Buy-back.
2. Pursuant to the resolution passed by the Board on November 5, 2018, the Company was authorised to Buy-back its fully paid-up equity shares each having a face value of Rs. 2 each ("**Equity Shares**") from the open market through the Stock Exchanges using the electronic trading facilities of the BSE Limited ("**BSE**") and the National Stock Exchange of India Limited ("**NSE**") (collectively, referred to as "**Stock Exchanges**") at a maximum price not exceeding Rs. 1,000 (Rupees One Thousand only) per Equity Share ("**Maximum Buy-back Price**") payable in cash for an aggregate amount not exceeding Rs. 2,500 Millions (Rupees Two Thousand Five Hundred Millions only) ("**Maximum Buy-back Size**") excluding any other expenses incurred or to be incurred for the Buy-back like filing fees payable to SEBI, Stock Exchanges fees, advisors' fees, public announcement, publication expenses, transaction cost viz., brokerage, applicable taxes such as securities transaction tax, stamp duty, etc., and any other incidental and related expenses ("**Transaction Costs**").
3. The Buy-back was commenced on November 19, 2018 in accordance with the provisions of the Buy-back Regulations. In this regard, please be informed that the Company has bought back 30,00,000 (Thirty Lakhs) Equity Shares at an average price of Rs. 621.32 (Rupees Six Hundred Twenty One and Paise Thirty Two only) per Equity Share (price calculated has been rounded to the nearest paise). Accordingly, the Company deployed approximately Rs. 1,864 Millions (Rupees One Thousand Eight Hundred Sixty Four Millions only) (excluding Transaction Costs), which represents approximately 74.56% of Maximum amount of Buy-back Size. Consequently, the Buy-back committee of the Company *vide* resolution dated May 16, 2019 *inter-alia* resolved to close the Buy-back and thereby the Company announces the closure of the Buy-back with effect from closing market hours of May 16, 2019.

For details of the pre and post Buy-back shareholding pattern of the Company, please refer **Annexure - A**.

We request you to kindly take this on record.

Thanking you,

Yours faithfully,

For **Natco Pharma Limited**



M Adinarayana

Company Secretary &

Vice President (Legal & Corp Affairs)



Encl: as above



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

ANNEXURE - A

The shareholding pattern of the Company, pre Buy-back and post Buy-back, is as under:

Category of Shareholder	Pre Buy-back*		Post Buy-back#	
	Number of Shares	% to the existing Equity Share capital	Number of Shares	% to post Buy-back Equity Share capital
Promoters and Promoter Group	8,90,81,645	48.21	8,90,81,645	49.01
Mutual Funds/Alternative Investment Funds/Financial Institutional/Banks	1,13,76,488	6.16	9,26,80,490	50.99
Foreign Portfolio Investors/ Foreign Institutional Investors	4,48,01,441	24.25		
Bodies Corporate	49,15,790	2.66		
Indian Public/Clearing member/IEPF/Trusts	3,31,72,537	17.95		
NRIs/ Foreign Nationals/Overseas Body Corporate	14,14,234	0.77		
Total	18,47,62,135	100.00	18,17,62,135	100.00

* As on November 5, 2018

4,84,357 Equity Shares Bought back are under the process of extinguishment

For NATCO Pharma Limited

M. ADINARAYANA
Company Secretary &
Vice President (Legal & Corp Affairs)